Reports (7) have indicated a significant elevation of IL-17 and IFN-γ levels in the serum of vitiligo patients, which significantly decrease post-treatment, while IL-10 is markedly reduced in the serum, displaying immune suppression. The gene discussed is IL17A; the disease is vitiligo.